On March 25, 2025 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, reported two upcoming presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois (Press release, Agenus, MAR 25, 2025, View Source [SID1234651418]). The presentations continue to build momentum for Agenus’ neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster featuring new data from the advanced hepatocellular carcinoma (HCC) cohort of a Phase 1 study evaluating BOT/BAL in patients with advanced solid tumors. Data from two separate, independent studies of neoadjuvant treatment with BOT/BAL in colorectal cancer–UNICORN and NEST– were presented earlier this year at ASCO (Free ASCO Whitepaper)-GI.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation Details:
Presentation Title: Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: First results of the pan-cancer NEOASIS study (NCT06279130)
Presenting Author: Myriam Chalabi, MD, Netherlands Cancer Institute
Session Title: Aiming for Cure: Adjuvant and Neoadjuvant Approaches
Session Date and Time: 4/28/2025; 2:30:00 – 4:30:00 PM CT
Abstract Presentation Number: CT130
Poster Presentation Details:
Presentation Title: Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma (NCT03860272)
Presenting Author: Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center
Session Title: Late-Breaking Research: Clinical Research 3
Session Date and Time: 4/29/2025; 2:00 – 5:00 PM CT
Location : Poster Section 53
Poster Board Number: 9
Abstract Presentation Number: LB365
About Botensilimab (BOT)
Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Approximately 1,100 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.
About Balstilimab (BAL)
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.